Pharmacyclics Receives Average Recommendation of “Buy” from Brokerages (NASDAQ:PCYC)
Pharmacyclics (NASDAQ:PCYC) has received an average rating of “Buy” from the nineteen ratings firms that are covering the stock, Analyst Ratings Network.com reports. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $155.33.
A number of analysts have recently weighed in on PCYC shares. Analysts at William Blair raised their price target on shares of Pharmacyclics from $150.00 to $180.00 in a research note on Tuesday, August 5th. They now have an “outperform” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $180.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $152.00 price target on the stock, up previously from $150.00.
Pharmacyclics (NASDAQ:PCYC) traded up 2.18% on Wednesday, hitting $121.3092. 105,018 shares of the company’s stock traded hands. Pharmacyclics has a 52-week low of $82.51 and a 52-week high of $154.89. The stock’s 50-day moving average is $103.0 and its 200-day moving average is $108.1. The company has a market cap of $9.131 billion and a price-to-earnings ratio of 106.09.
Pharmacyclics (NASDAQ:PCYC) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.03. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $95.88 million. During the same quarter in the previous year, the company posted $0.25 earnings per share. The company’s revenue for the quarter was up 106.6% on a year-over-year basis. On average, analysts predict that Pharmacyclics will post $0.36 earnings per share for the current fiscal year.
In other Pharmacyclics news, Insider Jesse Mcgreivy sold 34,062 shares of the company’s stock on the open market in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $120.92, for a total transaction of $4,118,777.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.